Inari Medical

NARI65

$50.65arrow_drop_down0.61%-$0.31

NARI65

$50.65

arrow_drop_down0.61%-$0.31

Performance History

Key Stats
Open	$50.61
Prev. Close	$51.32
EPS	-1.35
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	49.00	51.35
52 Week Range	36.73	69.40

Ratios







EPS	-1.35

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Inari Medical (NARI)

Inari Medical Inc (NASDAQ: NARI) is a medical device company that focuses on developing innovative technologies to treat vascular conditions. With a commitment to revolutionizing the way vascular diseases are treated, Inari Medical Inc has gained recognition as a leader in the field. As of the latest market close, Inari Medical Inc's stock price was recently quoted at $85.32.

Investors and analysts closely follow Inari Medical Inc's stock, looking for insights into the company's performance and potential. News related to Inari Medical Inc often triggers market reactions and influences the stock price. Therefore, staying updated with the latest Inari Medical Inc stock news is crucial for investors and traders alike.

Websitecall_made

Sector: Healthcare
Industry: Medical Devices
CEO: Mr. Andrew J. Hykes
Headquarters: Irvine
Employees: 1100
Exchange: NASDAQ

Keep an eye on Inari Medical

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Inari Medical 's (NARI) price per share?

The current price per share for Inari Medical (NARI) is $50.66. The stock has seen a price change of -$0.31 recently, indicating a -0.62% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Inari Medical (NARI)?

For Inari Medical (NARI), the 52-week high is $69.4, which is 37.01% from the current price. The 52-week low is $36.73, the current price is 37.91% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Inari Medical (NARI) a growth stock?

Inari Medical (NARI) has shown an average price growth of -7.34% over the past three years. It has received a score of 27 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Inari Medical as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Inari Medical (NARI) stock price performance year to date (YTD)?

As of the latest data, Inari Medical (NARI) has a year-to-date price change of -22.97%. Over the past month, the stock has experienced a price change of 15.47%. Over the last three months, the change has been 1.64%. Over the past six months, the figure is 9.81%.

help

Is Inari Medical (NARI) a profitable company?

Inari Medical (NARI) has a net income of -$1.64M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 88.03% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.34% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $493.63M, with a revenue growth rate of 28.73%, providing insight into the company's sales performance and growth. The gross profit is $434.56M. Operating income is noted at -$14.03M. Furthermore, the EBITDA is $15.18M.

help

What is the market capitalization of Inari Medical (NARI)?

Inari Medical (NARI) has a market capitalization of $2.98B. The average daily trading volume is 50.58, indicating the stock's liquidity and investor engagement.

News

SECURITIES LAW VIOLATIONS

DERIVATIVE LAWSUITS

Oct 29, 2024

Inari Medical, Hertz Global, Fastly, and Ryvyl Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

DEXCOM

EARNINGS

REVENUE

CONTINUOUS GLUCOSE MONITORING

Jul 23, 2024

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings - Zacks Investment Research